Jim is Managing Director of Retrogenix, having co-founded the company in 2008. This followed 10+ years in management within the biotechnology (Oxford BioMedica) and pharmaceutical industry (AstraZeneca). He is a biologist by training, and obtained his PhD at Manchester University, UK, in 1997.
EAC 2017 Day 1, Tuesday 31st October 2017 @ 11:35
Plenary Roundtable Discussion Session
- A powerful approach to identify specific receptors for phenotypic antibodies and immune checkpoint ligands
- Efficient off-target profiling of biotherapeutics including antibodies, ADCs, scFvs and whole CAR T cells
back to speakers